gene expression in response to manipulating the actin cytoskeleton in chondrocytes. Methods: Chondrocytes isolated from embryonic mice growth plates were plated in high density monolayer cultures and treated for 24 hours with vehicle, 10 mM Y27632 (inhibits Rho/ROCK signaling), 1 mM cytochalasin D (inhibits actin polymerization) or 50 nM jasplakinolide (promotes actin polymerization). RNA was isolated, and then hybridized to Affymetrix MOE4.0 chips. Bioinformatic analysis (MAS5.0) was performed and probe sets demonstrating a significant, at least 1.5-fold change and reliable signal were considered for further analysis. These data were compared to our previous microarray analyses of chondrocyte differentiation in vitro and in vivo (growth plate zones of microdissected tibia, time course of micromass cultures differentiating from mesenchymal cells to hypertrophy) we have previously analyzed. Results: Inhibition of actin polymerization by cytochalasin D resulted in the most compelling data in comparison to other actin manipulations. We observed that treating growth plates with cytochalasin D resulted in very large bones consisting entirely of cells with hypertrophic morphology. Analysis of the gene set revealed that most genes that were upregulated were similarly regulated in other models of chondrocyte differentiation to hypertrophy, suggesting that cytochalasin D stimulates chondrocyte hypertrophy, a novel finding. We continued our studies by comparing gene sets with other models of chondrocyte hypertrophy and identified the nuclear receptor, Rora as a common gene upregulated in all 3 models studied. We found that Rora is most highly expressed in the hypertrophic portion of the growth plate and is expressed throughout growth plates of cytochalasin D treated bones. Additionally, multiple targets of Rora are also increased in chondrocytes treated with cytochalasin D, such as fatty acid binding protein 4, lipoprotein lipase and CD36 (a receptor previously implicated in osteoarthritis). We also show that stimulation of Rora by its ligand cholesterol results in a phenotype similar to chondrocyte hypertrophy. These data suggest that cholesterol signaling through Rora contributes to chondrocyte hypertrophy. Interestingly, because it has been shown in other cell types that Rora expression is regulated by Hif1a, we assessed and confirmed increased levels of Hif1a in the hypertrophic region of the growth plate and throughout the growth plates of bones treated with cytochalasin D. Similarly, Rora and Hif1a expression was upregulated in chondrocytes with cartilagespecific deletion of the Rac1 gene. Conclusions: Identification of regulators of chondrocyte hypertrophy will be essential in preventing pathological differentiation of articular chondrocytes in osteoarthritis. Our data implicate the nuclear receptor Rora and its activator cholesterol in stimulating chondrocyte hypertrophy. These data have far reaching implications for preventing and possibly minimalizing the severity of osteoarthritis.
gene expression in response to manipulating the actin cytoskeleton in chondrocytes. Methods: Chondrocytes isolated from embryonic mice growth plates were plated in high density monolayer cultures and treated for 24 hours with vehicle, 10 mM Y27632 (inhibits Rho/ROCK signaling), 1 mM cytochalasin D (inhibits actin polymerization) or 50 nM jasplakinolide (promotes actin polymerization). RNA was isolated, and then hybridized to Affymetrix MOE4.0 chips. Bioinformatic analysis (MAS5.0) was performed and probe sets demonstrating a significant, at least 1.5-fold change and reliable signal were considered for further analysis. These data were compared to our previous microarray analyses of chondrocyte differentiation in vitro and in vivo (growth plate zones of microdissected tibia, time course of micromass cultures differentiating from mesenchymal cells to hypertrophy) we have previously analyzed. Results: Inhibition of actin polymerization by cytochalasin D resulted in the most compelling data in comparison to other actin manipulations. We observed that treating growth plates with cytochalasin D resulted in very large bones consisting entirely of cells with hypertrophic morphology. Analysis of the gene set revealed that most genes that were upregulated were similarly regulated in other models of chondrocyte differentiation to hypertrophy, suggesting that cytochalasin D stimulates chondrocyte hypertrophy, a novel finding. We continued our studies by comparing gene sets with other models of chondrocyte hypertrophy and identified the nuclear receptor, Rora as a common gene upregulated in all 3 models studied. We found that Rora is most highly expressed in the hypertrophic portion of the growth plate and is expressed throughout growth plates of cytochalasin D treated bones. Additionally, multiple targets of Rora are also increased in chondrocytes treated with cytochalasin D, such as fatty acid binding protein 4, lipoprotein lipase and CD36 (a receptor previously implicated in osteoarthritis). We also show that stimulation of Rora by its ligand cholesterol results in a phenotype similar to chondrocyte hypertrophy. These data suggest that cholesterol signaling through Rora contributes to chondrocyte hypertrophy. Interestingly, because it has been shown in other cell types that Rora expression is regulated by Hif1a, we assessed and confirmed increased levels of Hif1a in the hypertrophic region of the growth plate and throughout the growth plates of bones treated with cytochalasin D. Similarly, Rora and Hif1a expression was upregulated in chondrocytes with cartilagespecific deletion of the Rac1 gene. Conclusions: Identification of regulators of chondrocyte hypertrophy will be essential in preventing pathological differentiation of articular chondrocytes in osteoarthritis. Our data implicate the nuclear receptor Rora and its activator cholesterol in stimulating chondrocyte hypertrophy. These data have far reaching implications for preventing and possibly minimalizing the severity of osteoarthritis.
TRANSFORMING GROWTH FACTOR ALPHA AND ENDOTHELIN RECEPTOR A SIGNALING IN OSTEOARTHRITIS
S.E. Usmani, C.T. Appleton, F. Beier. The University of Western Ontario, London, ON, CANADA Purpose: Osteoarthritis (OA) involves the degeneration of articular cartilage by catabolic factors. Previously, we determined that transforming growth factor alpha (TGF alpha) gene expression was upregulated in articular chondrocytes in an experimental OA model. Furthermore we demonstrated that TGF alpha suppressed chondrocyte phenotype and specifically induced expression of catabolic factors including matrix metalloproteinase-13. Thus we identified TGF alpha as a candidate causal factor in OA. Our subsequent goal was to determine downstream targets of TGF alpha. Interestingly, microarray data from our OA model indicate that endothelin receptor A (ETA) expression is also upregulated in the disease state. Since ETA has already been implicated in OA and other age-related diseases we decided to investigate whether there was a connection between TGF alpha and ETA signaling. The purpose of the current study was to (1) examine the upregulation of ETA in our experimental OA model, (2) determine the effects of TGF alpha on ETA expression, (3) evaluate whether the catabolic effects of TGF alpha can be inhibited by blocking ETA. Methods: RNA and histological cartilage sections from our rodent OA model were evaluated for ETA gene and protein expression by realtime PCR and immunohistochemistry respectively. Next primary articular chondrocytes were isolated from newborn Sprague Dawley rats, grown in monolayer cultures, and treated with TGF alpha (10 ng/ml) for up to 3 days. RNA was isolated from cultures and the expression of genes implicated in OA was assessed by real-time PCR. We then isolated articular cartilage organ culture explants and treated them with TGF alpha for up to 7 days. Explants were sectioned and immunostained for both ETA and inducible nitric oxide synthase (iNOS). Next we used an endothelin receptor inhibitor in an attempt to block some of TGF alpha's catabolic effects. Chondrocyte cultures were treated with either vehicle, TGF alpha, inhibitor (10 mM), or a combination of both for 48 hours. RNA was isolated and real-time PCR was performed for genes including Mmp13, Col2a1, and Agc1. Results: Data revealed a significant increase in ETA gene expression in OA animals compared to controls. There also appeared to be deeper ETA staining in cartilage from OA animals compared to controls. In cell cultures, Cxcr4, Tgfa and Il1b gene expression did not change after treatment, while the expression of Ednra (ETA gene) and Tnfa increased in response to TGF alpha. Immunohistochemistry showed that explants treated with TGF alpha expressed more ETA than did controls. The endothelin receptor inhibitor did not appear to block TGF alpha's induction of Mmp13 or inhibition of Col2a1 and Agc1 expression by TGF alpha. Organ culture explants demonstrated an increase in iNOS expression in TGF alpha-treated tissues compared to controls. Our current cell cultures studies suggest that TGF alpha treatment results in increased production of nitric oxide that can be partially blocked by inhibition of endothelin signaling. Conclusions: ETA expression was upregulated in our animal model of OA as well as in TGF alpha-treated chondrocyte cultures and articular cartilage organ cultures. Preliminary data suggest that blocking ETA may inhibit a TGF alpha-induced increase in nitric oxide production. Thus, in addition to TGF alpha, ETA may be another therapeutic target for OA treatment. While blocking ETA did not appear to alter TGF alpha's effects on Mmp13, Col2a1 and Agc1 expression, future experiments will focus on studying protein levels of these genes. Purpose: Although EPAS1 plays essential roles in hypoxia and many pathogenic conditions, the function of EPAS1 in articular chondrocytes is unclear. In this study, we characterized a role of EPAS1 in cartilage destruction. Methods: EPAS1 expression and function in primary culture rabbit articular chondrocytes were studied by RT-PCR and qRT-PCR analysis. A role of EPAS1 in MMP expression was determined by reporter gene assay. In vivo role of EPAS1 was examined by using collagenase-induced osteoarthritis model using EPAS1 deficient (EPAS1 +/− ) mouse. Results: In primary culture articular chondrocytes, EPAS1 expression was significantly increased during dedifferentiation caused by interleukin1beta (Il-1b), epidermal growth factor, retinoic acid, or serial subculture as monolayer. Dedifferentiation of chondrocyte accompanies induction of several matrix metalloproteinases (MMPs) expression such as MMP-1, -3, -9, -12, and -13, but not MMP-2, -14, and -15. Overexpression of EPAS1 by adenovires-EPAS1 induced MMP-1, -3, -9, -12, and -13 expressions, whereas knockdown of EPAS1 by siRNA blocked Il-1b-induced expression of these MMPs. Regulatory mechanism of MMP expression was further examined by reporter gene containing individual MMP promoter. Reporter gene activity of MMP-1, -3, -9, -12, and -13 increased by EPAS1 transfection, and the increased activity was blocked by point mutation of EPAS1 binding site (−CGTG−) or dominant negative EPAS1. In vivo role of EPAS1 was examined by using EPAS1 deficient (EPAS1 +/− ) mice, and found that EPAS1 knockdown significantly reduced collagenase-induced osteoarthritis. Conclusions: We demonstrated that EPAS1 in chondrocytes regulates expression of MMP-1, -3, -9, -12, and -13, and EPAS1 knockdown reduces collagenase-induced osteoarthritis in mice. Our results suggest that EPAS1 may play a role in cartilage destruction by modulating MMP expression.
